Eduovisual
Female Reproductive & Breast
Breast cancer screening: USPSTF and patient counseling
— Breast cancer is the most common non-skin cancer in US women; ~1 in 8 lifetime risk
— Second leading cause of female cancer death (after lung); ~42,000 US deaths/year
— Incidence rises sharply after age 40, peaks in 70s; mortality reduced ~20–30% with mammographic screening in average-risk women
— Step 3 tests longitudinal decisions: when to start, how often, when to stop, how to counsel about benefits/harms, and how to integrate shared decision-making for women 40–49
— Expect ambulatory vignettes asking what to order today at a well-woman visit, and what to schedule next at 1–2 year intervals
— Frequent overlap with biostatistics (lead-time bias, length bias, NNS), ethics (informed refusal), and health systems (insurance coverage under ACA)
— Average risk: no personal history, no known pathogenic variant, no chest radiation 10–30 yrs, lifetime risk <15%
— Increased risk: lifetime risk 15–20% (dense breasts + family hx, atypical hyperplasia, LCIS)
— High risk: lifetime risk ≥20% by validated model (Tyrer-Cuzick, BRCAPRO, Claus), BRCA1/2 or other pathogenic variants, prior thoracic RT age 10–30, Li-Fraumeni, Cowden
— First-degree relative with premenopausal breast or ovarian cancer
— Ashkenazi Jewish ancestry with any family hx of breast/ovarian/pancreatic/prostate cancer
— Male relative with breast cancer
— Prior breast biopsy showing atypical ductal/lobular hyperplasia or LCIS
— History of mantle radiation for Hodgkin lymphoma in adolescence
Board pearl: The 2024 USPSTF update lowered the recommended start age to 40 (Grade B) with biennial mammography through 74 for average-risk women — a major change from the prior 2016 guidance. Memorize this; it is the single highest-yield testable fact on the topic.
— A 42- to 74-year-old asymptomatic woman presents for an annual well-woman exam or Medicare wellness visit
— No palpable mass, no nipple discharge, no skin changes
— Stem buries the answer in family history, prior biopsies, reproductive history, or ancestry
— Your task: choose start age, modality, interval, and whether to add MRI or genetic testing
— Age at menarche (<12 increases risk) and age at menopause (>55 increases risk)
— Parity and age at first live birth (nulliparity or first birth >30 = higher risk)
— Breastfeeding (protective, dose-dependent)
— Hormone exposure: combined estrogen-progestin HRT >3–5 yrs ↑ risk; OCP modest transient ↑
— Alcohol use (≥1 drink/day raises risk ~10%); BMI (postmenopausal obesity ↑ risk)
— Prior chest wall radiation age 10–30 — annual MRI + mammogram starting 8 yrs post-RT or age 25
— First- AND second-degree relatives, both maternal and paternal lineages
— Ages at diagnosis, bilateral disease, male breast cancer, ovarian, pancreatic, prostate (metastatic/high-grade), melanoma
— Ashkenazi Jewish ancestry is itself a referral trigger if any qualifying cancer
— Previous biopsies and exact pathology (fibroadenoma vs ADH/ALH/LCIS dramatically changes risk)
— Breast density on prior mammogram (categories C/D = dense)
— Symptoms suggesting diagnostic rather than screening evaluation: lump, focal pain, bloody/spontaneous unilateral discharge, skin retraction, nipple inversion
Key distinction: A patient with a palpable mass is no longer in the screening pathway — she needs diagnostic mammogram + targeted US regardless of age, and a normal recent screening mammogram does not rule out cancer. Step 3 loves to test this pivot from screening to diagnostic workup.
— USPSTF: insufficient evidence (I statement) to recommend for or against CBE in average-risk women
— ACS no longer recommends routine CBE for average-risk women at any age
— ACOG considers CBE optional 25–39 q1–3 yrs and annually ≥40 after shared decision-making
— On Step 3, CBE alone is never the correct answer for screening — mammography is
— Not recommended by USPSTF or ACS — large RCTs (Shanghai, Russia) showed no mortality benefit and increased benign biopsies
— Replace with "breast self-awareness": know what's normal, report changes
— Counseling point on exam: don't teach formal monthly BSE; do encourage awareness
— Inspection: symmetry, skin dimpling, peau d'orange, nipple inversion/retraction (new), erythema
— Palpation: systematic vertical strip technique, supraclavicular/infraclavicular/axillary nodes
— Document any dominant mass with size, location (clock face + cm from nipple), mobility, tenderness
— Discrete palpable mass — diagnostic mammo + US (US first if <30)
— Unilateral bloody or serous spontaneous discharge — diagnostic mammo + ductography or MRI
— Skin changes suggesting inflammatory breast cancer: rapid-onset erythema, edema, warmth covering ≥1/3 breast — urgent punch biopsy of skin + core biopsy, do not wait for antibiotic trial beyond 1–2 weeks
— Paget disease appearance: scaly, eczematous nipple — punch biopsy
CCS pearl: In a CCS case where a screening visit reveals a new palpable mass, the correct action sequence is: (1) diagnostic mammogram and targeted ultrasound, (2) core needle biopsy if BI-RADS 4 or 5, (3) referral to breast surgical oncology. Ordering "screening mammogram" instead of "diagnostic mammogram" is a classic point-loser.
— Digital mammography or digital breast tomosynthesis (DBT/3D) — both acceptable per USPSTF 2024
— DBT reduces recall rates and may improve cancer detection in dense breasts; not yet proven to reduce mortality but increasingly standard
— Two views per breast: craniocaudal (CC) and mediolateral oblique (MLO)
— 0: Incomplete, need additional imaging (recall) — most common screening result requiring action
— 1: Negative — routine interval
— 2: Benign findings (cyst, calcified fibroadenoma) — routine interval
— 3: Probably benign, <2% malignancy — short-interval follow-up at 6 months
— 4: Suspicious (4A/B/C) — core needle biopsy
— 5: Highly suggestive of malignancy (>95%) — core needle biopsy + surgical consult
— 6: Known biopsy-proven malignancy
— FDA now requires density notification on every mammogram report (Sept 2024 rule)
— Categories: A (almost entirely fatty), B (scattered), C (heterogeneously dense), D (extremely dense) — C+D = "dense breasts"
— Dense breasts both mask cancers and independently increase risk ~1.2–2x
— Counseling: discuss supplemental screening options; no USPSTF recommendation for or against supplemental US/MRI in dense breasts (I statement)
— Sensitivity ~85% overall, ~65% in dense breasts
— Specificity ~90%; false-positive rate over 10 years of biennial screening ~50% cumulative
— Biopsy rate from screening ~7–10% over a decade; overdiagnosis estimated 10–20% of detected cancers
Board pearl: A BI-RADS 0 result is not a normal mammogram — the correct next step is diagnostic mammogram ± targeted ultrasound, not "repeat in 1 year." This is one of the most-missed Step 3 management questions on the topic.
— Indicated annually (alternating q6mo with mammogram) for women with lifetime risk ≥20% by validated model
— Specific high-risk groups for MRI + mammogram annually:
— BRCA1/2 carriers and untested first-degree relatives
— TP53 (Li-Fraumeni), PTEN (Cowden), CDH1, STK11, PALB2
— Chest radiation between ages 10–30 (e.g., Hodgkin survivors) — start 8 yrs post-RT or age 25, whichever later, not before 25
— MRI is more sensitive (~90–95%) but less specific than mammography → more false positives and biopsies
— Requires IV gadolinium; avoid in eGFR <30 and pregnancy
— Option for supplemental screening in dense breasts when MRI is contraindicated or unavailable
— Increases cancer detection by ~3–4 per 1,000 but markedly increases false positives
— Not a substitute for mammography
— Personal or family hx suggesting BRCA1/2 or other hereditary syndromes
— Use a brief familial-risk tool first: Ontario FHAT, Manchester, 7-Question Family History Screen, Tyrer-Cuzick
— If positive screen → formal genetic counseling, then testing if indicated
— Do NOT order BRCA testing directly without counseling on most exams
— Gail (BCRAT): 5-year and lifetime risk for average-risk women ≥35; used to qualify for risk-reducing endocrine therapy (5-yr risk ≥1.67%)
— Tyrer-Cuzick (IBIS): incorporates extended family hx and density; best for identifying ≥20% lifetime risk for MRI eligibility
— BRCAPRO/Claus: family-history-based, estimate mutation probability
Step 3 management: A 35-year-old woman with a BRCA1 mutation should begin annual breast MRI at age 25, add annual mammography at age 30 (alternating every 6 months), and be counseled on risk-reducing bilateral mastectomy and bilateral salpingo-oophorectomy by age 35–40 after childbearing.
— Age 40–74: biennial screening mammography (USPSTF Grade B, 2024 update)
— Age 75+: insufficient evidence (I) — individualize based on life expectancy ≥10 years, comorbidities, patient preference; stop when life expectancy <10 yrs
— Age <40: do not screen routinely
— USPSTF (2024): 40–74, biennial
— ACS (2015): offer annually 40–44, annual 45–54, then biennial or annual 55+, continue while life expectancy ≥10 yrs
— ACOG: offer at 40, start by 50, q1–2 yrs through ≥75
— NCCN: annual 40+
— On boards, default to USPSTF unless the stem specifies otherwise
— Annual mammography
— Consider supplemental MRI (shared decision-making; not strongly evidence-based)
— Discuss risk-reducing endocrine therapy (tamoxifen, raloxifene, aromatase inhibitor) — USPSTF Grade B for women ≥35 at increased risk and low harm risk
— Annual mammography + annual breast MRI, often offset by 6 months
— Begin earlier than 40 based on syndrome (see chunk 5)
— Genetic counseling, consider risk-reducing surgery
— Absolute mortality benefit modest in this age group (~3 deaths prevented per 10,000 screened over 10 yrs)
— Higher false-positive and biopsy rates
— Document discussion of benefits/harms; respect informed refusal
Board pearl: A woman with one first-degree relative diagnosed with breast cancer at age 45 has roughly double the average risk — that alone often does not push her to ≥20% lifetime, so she still gets standard mammographic screening (perhaps starting at age 30 or 10 years before the relative's diagnosis per some guidelines) — not automatically MRI. Run a Tyrer-Cuzick before adding MRI.
— Offer risk-reducing medications to women ≥35 at increased risk (5-yr Gail risk ≥3%, or ≥1.67% with low risk of adverse effects) and low risk of medication harms
— Not for average-risk women; not for women with prior thromboembolism (for SERMs)
— Tamoxifen 20 mg PO daily × 5 years
— Premenopausal AND postmenopausal women
— Reduces invasive breast cancer ~40–50%
— Raloxifene 60 mg PO daily × 5 years
— Postmenopausal only
— Slightly less effective than tamoxifen but less endometrial cancer and fewer thromboembolic events
— Aromatase inhibitors (exemestane 25 mg or anastrozole 1 mg daily × 5 yrs)
— Postmenopausal only
— Most effective (~50–65% reduction); off-label for prevention but supported by MAP.3 and IBIS-II trials
— Adverse effects: arthralgias, bone loss → monitor DXA
— Tamoxifen: endometrial cancer (postmenopausal), VTE/PE, stroke, cataracts, hot flashes, vaginal discharge
— Any postmenopausal bleeding on tamoxifen → endometrial biopsy
— Raloxifene: VTE, hot flashes, leg cramps; no increased endometrial cancer
— AIs: bone loss/fractures, arthralgias, vaginal dryness, ↑ cardiovascular events in some studies
— History of DVT/PE, stroke, TIA → avoid SERMs
— Pregnancy/lactation → avoid all
— Concurrent strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) ↓ tamoxifen efficacy — choose venlafaxine or citalopram for hot flashes/depression
— Average-risk women without elevated Gail score
— Women with contraindications outweighing benefit
— Document shared decision-making with discussion of NNT (~50 over 5 yrs to prevent one cancer)
Step 3 management: A 55-year-old postmenopausal woman with ADH on biopsy and 5-yr Gail risk of 4% — best preventive pharmacotherapy is an aromatase inhibitor or raloxifene; tamoxifen acceptable but higher VTE/endometrial risk in this age group.
— Image-guided core needle biopsy is the standard — not excisional biopsy first, not FNA for solid masses
— Stereotactic biopsy for calcifications; US-guided for masses; MRI-guided for MRI-only lesions
— Place a clip at biopsy site for future localization
— Atypical ductal hyperplasia (ADH): surgical excision; upstaging to DCIS/invasive ~10–20%
— Lobular neoplasia (ALH, classic LCIS): observation acceptable if concordant; pleomorphic LCIS → excise
— Radial scar/complex sclerosing lesion: excise if atypia present or imaging discordance
— Papilloma with atypia: excise
— Bilateral risk-reducing mastectomy (BRRM): reduces breast cancer risk >90% in BRCA carriers
— Consider in BRCA1/2, TP53, PTEN, prior chest RT
— Nipple-sparing options when oncologically appropriate
— Bilateral salpingo-oophorectomy (BSO): in BRCA carriers by age 35–40 (BRCA1) or 40–45 (BRCA2)
— Reduces ovarian cancer ~80–90% AND breast cancer ~50% if premenopausal
— Counsel on surgical menopause: vasomotor symptoms, bone loss, cardiovascular; short-course HRT acceptable until natural menopause age if no personal cancer history
— Discuss alternatives: intensive surveillance, chemoprevention
— Irreversibility; fertility implications for BSO
— Reconstruction options and timing for mastectomy
— Residual risk (~1–5%) even after mastectomy due to residual breast tissue
— ACA mandates coverage of USPSTF Grade A/B screening services with no cost-sharing — includes screening mammograms and BRCA counseling/testing in qualifying women
— Diagnostic mammograms historically had cost-sharing; many states now mandate coverage
CCS pearl: Order the diagnostic mammogram + targeted US for any palpable mass, escalate to core needle biopsy for BI-RADS 4/5, and refer to breast surgical oncology for biopsy-proven malignancy or high-risk lesions requiring excision. Do not order PET, CT, or bone scan in early-stage screening-detected cancer.
— USPSTF: I statement — insufficient evidence
— ACS and ACOG: continue while life expectancy ≥10 years
— Use validated tools: ePrognosis, Charlson, Lee Index
— Stop screening when life expectancy <10 yrs, severe dementia, frailty, or patient prefers cessation
— Frame as: "screening helps when you'd live long enough to benefit from finding an early cancer"
— Document conversation; this is a frequent ethics/communication vignette
— Avoid abrupt "you're too old" framing — patient-centered language
— Severe CHF, ESRD on dialysis, metastatic non-breast cancer, advanced COPD on home O2 — generally stop
— Mild-moderate HTN, controlled DM, osteoarthritis — continue if functional
— Mammography: no contrast, no renal limitation
— Breast MRI uses gadolinium — avoid in eGFR <30 (risk of nephrogenic systemic fibrosis with older linear agents; newer macrocyclic agents lower but still cautious)
— Use non-contrast techniques or supplemental US if MRI needed
— Iodinated contrast not used in standard breast imaging
— Imaging unaffected
— Tamoxifen metabolized by CYP2D6/3A4 → caution in severe hepatic dysfunction; not absolutely contraindicated
— Aromatase inhibitors: use with caution in severe hepatic impairment; exemestane reduce dose
— Continue screening if life expectancy ≥10 yrs (young transplant candidates) — otherwise individualize
— Average life expectancy on HD for elderly is often <5 yrs → many do not benefit
— Capacity assessment for screening decisions
— Surrogate decision-maker for advanced dementia
— Consider whether a positive result would change management — if not, stop screening
Board pearl: A 78-year-old woman with well-controlled HTN, independent ADLs, and estimated 12-year life expectancy should be offered continued biennial mammography — age alone is not a reason to stop. Conversely, a 70-year-old with metastatic colon cancer should not undergo breast screening.
— Screening mammography not routinely indicated during pregnancy/lactation in average-risk women
— If symptomatic (palpable mass): ultrasound first, then mammogram with abdominal shielding (fetal dose negligible) if needed
— Breast MRI without gadolinium acceptable; avoid gadolinium in pregnancy (Category C, crosses placenta)
— Pregnancy-associated breast cancer is often diagnosed late — maintain low threshold for biopsy of persistent masses
— Mammography is feasible but dense lactating tissue ↓ sensitivity
— Pump or breastfeed immediately before imaging
— Core biopsy safe; small milk fistula risk
— Transgender women (assigned male at birth) on feminizing hormones ≥5 years: screen with mammography starting age 40–50 every 1–2 years (ACR/limited evidence)
— Transgender men (assigned female at birth):
— Without chest/top surgery: standard female screening guidelines
— After bilateral mastectomy: routine screening not recommended; chest wall exam
— Use inclusive language; document anatomy inventory not just gender identity
— Begin mammography at age 30 or 10 years before youngest affected first-degree relative (whichever later)
— Add annual MRI if lifetime risk ≥20%
— Li-Fraumeni (TP53): annual MRI starting age 20, mammogram starting 30 (avoid radiation when possible)
— Cowden (PTEN): annual MRI starting 30–35
— Hodgkin survivors with chest RT age 10–30: MRI + mammogram annually, begin 8 yrs post-RT or age 25, not before 25
Step 3 management: A 27-year-old BRCA1 carrier — begin annual breast MRI now (age 25) and add mammography at age 30. Do not start mammography at 25 (radiation exposure to young breast tissue) and do not wait until 40.
— Cumulative ~50% over 10 years of annual screening 40–49; ~30% biennial
— Lead to anxiety, repeat imaging, biopsies
— Biopsy rate ~7–10% over a decade of biennial screening
— Counsel proactively: "About half of women screened over a decade will get called back for an extra image — most are not cancer"
— Sensitivity drops to ~65% in dense breasts (BI-RADS C/D)
— Interval cancers (diagnosed between screenings) ~15–25% of all screen-era cancers
— Counsel that a normal mammogram does not rule out cancer if new symptoms arise
— Detection of cancers (especially DCIS) that would never have caused symptoms
— Estimated 10–20% of screen-detected cancers
— Leads to overtreatment: surgery, radiation, endocrine therapy
— Active area of research (LORIS, COMET trials evaluating active monitoring for low-risk DCIS)
— Per screening mammogram: ~0.4 mSv (similar to 7 weeks background)
— Theoretical induced cancer risk: ~1 cancer per 1,000 women screened annually 40–80; outweighed by benefit
— Higher concern in young BRCA carriers → favor MRI before age 30
— Hematoma, infection (<1%), pneumothorax (stereotactic, rare)
— Vasovagal reactions
— Anxiety, distress, sleep disturbance after abnormal recall — often persists weeks even after benign resolution
— Address with clear, prompt communication and short turnaround on diagnostic imaging
— Lead-time bias: screening detects cancer earlier, apparent survival longer even if death date unchanged
— Length bias: screening preferentially detects slow-growing cancers, inflating apparent survival
— Mortality endpoints (not 5-yr survival) are the valid measure
Key distinction: Overdiagnosis (cancer would never harm) differs from overtreatment (treating a real cancer more aggressively than necessary). Both are screening harms, but overdiagnosis is upstream — addressing it requires changing detection thresholds (e.g., not biopsying low-risk calcifications) or treatment (active surveillance for low-risk DCIS).
— Biopsy-proven invasive cancer or DCIS
— BI-RADS 5 imaging pending biopsy logistics
— High-risk lesion on biopsy requiring excision (ADH, pleomorphic LCIS, papilloma with atypia, radial scar with atypia)
— Inflammatory breast cancer suspicion → urgent (within days)
— Positive family-history screening tool
— Personal hx of breast cancer ≤50, triple-negative ≤60, male breast cancer, bilateral disease, Ashkenazi Jewish with any qualifying cancer
— Two or more relatives with breast/ovarian/pancreatic/prostate cancer on same side
— Known familial mutation
— Do not order BRCA testing without counseling on Step 3 — wrong answer
— Lifetime risk ≥20%
— Known pathogenic variant
— Chest radiation history
— Atypical hyperplasia or LCIS — for chemoprevention discussion and surveillance planning
— All invasive cancers for staging, systemic therapy planning
— Consider for high-risk women considering chemoprevention if primary care unfamiliar
— Post-lumpectomy in invasive cancer and most DCIS
— Not part of screening pathway directly
— Inflammatory breast cancer with sepsis-like presentation requiring biopsy and rapid workup — usually expedited outpatient
— Locally advanced disease with airway, vascular, or pain crises — uncommon
— Abnormal screening → diagnostic imaging within 1–2 weeks
— BI-RADS 4/5 → biopsy within 1–2 weeks
— Biopsy result → patient communication within 5–7 days
— Cancer diagnosis → surgical/oncology consult within 2 weeks
CCS pearl: When biopsy returns invasive ductal carcinoma, the correct sequence is: (1) communicate result in person/phone within days, (2) refer to breast surgical oncology, (3) order staging based on stage — for clinical stage I/II without symptoms, no routine CT, bone scan, or PET; reserved for stage III+ or symptomatic disease per NCCN/ASCO Choosing Wisely.
— Most common benign condition, ages 30–50
— Cyclic bilateral nodularity, tenderness, often upper outer quadrants
— Imaging: scattered cysts, no discrete suspicious mass
— Management: supportive bra, caffeine reduction (weak evidence), NSAIDs
— Round, anechoic, posterior acoustic enhancement on US — BI-RADS 2
— No intervention unless symptomatic → aspirate if painful; cytology only if bloody fluid
— Complicated (internal echoes, no solid component): BI-RADS 3, follow-up
— Complex (solid component, thick septations): BI-RADS 4 → biopsy
— Most common benign solid mass, women <30
— US: well-circumscribed, oval, wider-than-tall, hypoechoic
— Manage: if classic imaging and <2 cm, observe; biopsy if >2 cm, growing, or atypical features
— Phyllodes tumor mimics fibroadenoma — usually larger, rapidly growing → excise
— Most common cause of unilateral bloody/serous nipple discharge
— Diagnose: ductography or MRI; excise (5–10% harbor atypia/malignancy)
— Lactational: Staph aureus → dicloxacillin or cephalexin, continue breastfeeding; abscess → US-guided aspiration
— Non-lactational/periductal: anaerobes, smokers → amoxicillin-clavulanate
— Persistent "mastitis" not responding to antibiotics in 1–2 weeks → biopsy to rule out inflammatory breast cancer
— Post-trauma, post-surgery, post-radiation
— Can mimic malignancy on imaging; oil cysts and rim calcifications are reassuring; biopsy if uncertain
— Subareolar, tender, often bilateral
— Workup if unilateral/hard/fixed → mammogram + US, rule out male breast cancer
Key distinction: Bloody unilateral spontaneous nipple discharge = papilloma until proven otherwise (and ~10% malignant). Bilateral milky discharge = galactorrhea — check prolactin, TSH, pregnancy test, review medications (antipsychotics, metoclopramide, SSRIs).
— Sebaceous/epidermal inclusion cysts: superficial, mobile, central punctum; not glandular
— Lipoma: soft, mobile, subcutaneous
— Hidradenitis suppurativa: intertriginous areas including inframammary fold
— Cellulitis: diffuse erythema, fever, leukocytosis; responds to antibiotics
— Tuberculous mastitis: rare, chronic sinus tracts in endemic areas
— Granulomatous mastitis (idiopathic): young parous women, often Hispanic; can mimic cancer; biopsy mandatory; treat with steroids ± methotrexate
— Mondor disease: superficial thrombophlebitis of breast vein — tender palpable cord; self-limited
— Lymphedema post-axillary dissection or radiation
— Pregnancy-related changes: physiologic enlargement, Montgomery tubercles
— Hyperprolactinemia: galactorrhea + amenorrhea — pituitary MRI if confirmed
— Thyroid disease: can cause galactorrhea (TRH stimulates prolactin)
— Costochondritis (Tietze): reproducible tenderness at costochondral junctions; not breast tissue
— Myofascial pain, herpes zoster (dermatomal pre-vesicular pain)
— Lymphoma, melanoma, lung, ovarian, renal — usually rapidly growing, multiple
— Biopsy distinguishes
— Male breast cancer: ~1% of all breast cancers; BRCA2 strong association; subareolar firm mass, often with nipple retraction → mammogram + US + biopsy
— Klinefelter, cirrhosis, exogenous estrogens increase risk
— Capsular contracture, implant rupture (silicone → MRI, saline → clinical)
— Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): late peri-implant seroma → aspirate and send for CD30 flow cytometry
Board pearl: A perimenopausal woman with persistent "mastitis" on her second course of antibiotics — the answer is punch biopsy of skin + core biopsy of breast tissue to rule out inflammatory breast cancer, not a third antibiotic course.
— Return to biennial mammography if average risk, ages 40–74
— Annual if increased/high risk
— Reinforce breast self-awareness: report any new lump, skin change, discharge, persistent pain
— Address modifiable risk factors:
— Alcohol ≤1 drink/day or less
— Physical activity ≥150 min/week moderate
— Weight management — postmenopausal obesity ↑ risk
— Limit combined HRT duration; use lowest effective dose, shortest duration for menopausal symptoms
— Breastfeeding when applicable
— Short-interval follow-up imaging at 6 months, then 6 and 12 months until stable for 2 years
— Patient education: <2% malignancy risk, but compliance with follow-up is critical
— Return to age-appropriate screening
— Document concordance between imaging and pathology — if discordant, re-biopsy or excise
— Annual mammography
— Consider MRI if lifetime risk ≥20%
— Offer risk-reducing endocrine therapy (see chunk 7)
— Lifetime risk after atypia: 4–5x baseline → ~30% lifetime
— Annual mammography of remaining breast tissue (ipsilateral if BCT, contralateral if mastectomy)
— Clinical exam q3–6 mo × 3 yrs, then q6–12 mo × 2 yrs, then annually
— Endocrine therapy adherence: tamoxifen or AI × 5–10 yrs
— Bone health on AI: DXA at baseline and q2 yrs; vitamin D, calcium, weight-bearing exercise
— Screening mammography covered without cost-sharing under ACA
— Diagnostic mammography and breast MRI vary by plan/state — assist patients with prior authorization
Step 3 management: After a benign concordant biopsy of a BI-RADS 4 mass, the correct interval is return to routine annual or biennial screening, NOT 6-month short-interval — that's for BI-RADS 3 (no biopsy performed) or post-surgical surveillance.
— Annual visit even when mammography is biennial — opportunity to update family history, reassess risk, address other preventive care
— Reassess Tyrer-Cuzick every 5 years or with significant family history changes
— Update breast density status with each mammogram report
— Current screening recommendation and rationale (USPSTF guidance)
— Benefits and harms discussed (false positives, overdiagnosis)
— Patient preferences and any informed refusal
— Breast self-awareness reminder (not formal BSE)
— Modifiable risk factors addressed
— Tamoxifen: annual gynecologic exam; any abnormal uterine bleeding → endometrial biopsy; check for VTE symptoms; ophthalmologic exam if visual symptoms
— Raloxifene: monitor for VTE, hot flashes
— AI: baseline DXA, repeat every 1–2 yrs; lipid panel periodically; bone-protective therapy if T-score < -2.0 or fracture risk elevated
— Coordinate alternating with mammography q6 months
— Address claustrophobia, contrast allergy ahead of scheduling
— Reassess renal function before each gadolinium study if borderline
— Positive pathogenic variant: cascade testing of first-degree relatives, refer for comprehensive risk management
— Variant of uncertain significance (VUS): manage based on family history, not the VUS; do not change relatives' care
— Negative result in a family with known mutation = true negative; family history alone if no known familial mutation
— USPSTF decision aids, BreastCancer.org, NCI's Breast Cancer Risk Assessment Tool
— Use teach-back to confirm understanding of biennial vs annual and what to do for new symptoms
— HEDIS breast cancer screening measure: women 50–74 screened within 27 months
— Recall and biopsy rates tracked by facility
Board pearl: A patient on tamoxifen for 4 years who develops postmenopausal vaginal bleeding — the correct next step is endometrial biopsy, not transvaginal ultrasound first (endometrial thickness criteria are unreliable on tamoxifen due to subepithelial cystic changes).
— Especially for ages 40–49: discuss modest absolute benefit (~3 deaths prevented/10,000 over 10 yrs) and harms (false positives, biopsies, overdiagnosis)
— Document the discussion; respect informed refusal
— Use validated decision aids when available
— Health literacy: present absolute numbers, not just relative risk reductions
— A competent patient may decline screening
— Document risks discussed, patient's reasoning, plan for revisiting at future visits
— Do not abandon care or coerce — but ensure the refusal is informed, not based on misconceptions
— Informed consent for genetic testing includes implications for relatives, insurance, employment
— GINA (Genetic Information Nondiscrimination Act): protects against health insurance and employment discrimination but NOT life, disability, or long-term care insurance — explicitly counsel this
— Pediatric testing for adult-onset cancer syndromes generally deferred until age of consent
— Not typically applicable to screening; cancer diagnoses reportable to state cancer registries (done automatically by labs/hospitals)
— Abnormal mammogram with no follow-up — leading cause of malpractice claims
— Closed-loop systems: track BI-RADS 0, 3, 4, 5 results to completion
— Communicate results to patients in plain language, not just MyChart-only when patient unlikely to access
— Reconcile imaging from outside facilities at every new patient visit
— Ensure interpreter services for non-English speakers
— Address transportation, scheduling, and cost barriers
— Tracking systems for women due for next screening
— A patient with limited English proficiency cannot give meaningful informed consent without a qualified medical interpreter — family members should not interpret for sensitive medical decisions
— Cognitive impairment does not automatically remove capacity for a specific decision
— Assess decision-specific capacity; involve surrogate when impaired
Step 3 management: A 45-year-old returns 14 months after a BI-RADS 0 mammogram — she never completed the recommended diagnostic imaging. The correct immediate action is to order diagnostic mammography + targeted ultrasound now and to implement a tracking process to prevent recurrence; do not simply schedule another routine screening mammogram.
— Start age 40 (changed from 50), biennial, through 74 — Grade B
— Applies to average-risk women including those with dense breasts and family hx not meeting high-risk criteria
— Insufficient evidence (I) for: supplemental US/MRI in dense breasts, screening ≥75
— BRCA1: lifetime breast 55–72%, ovarian 39–44%, more triple-negative, younger onset
— BRCA2: lifetime breast 45–69%, ovarian 11–17%, male breast, pancreatic, prostate
— Ashkenazi Jewish founder mutations: 185delAG, 5382insC (BRCA1), 6174delT (BRCA2)
— Surveillance: MRI age 25, mammogram age 30; risk-reducing BSO by 35–40 (BRCA1) or 40–45 (BRCA2)
— Increases: early menarche, late menopause, nulliparity, first birth >30, no breastfeeding, HRT (combined), alcohol, postmenopausal obesity, dense breasts, prior chest RT, atypical hyperplasia/LCIS
— Decreases: breastfeeding, multiparity with early first birth, physical activity, premenopausal lean BMI
— DCIS: non-invasive; mammographic microcalcifications; treat with lumpectomy + RT or mastectomy
— Invasive ductal: most common (~75%); spiculated mass
— Invasive lobular: subtle imaging, single-file cells on histology, often bilateral; E-cadherin negative
— Inflammatory: clinical diagnosis — peau d'orange, rapid onset; T4d; punch biopsy of skin
— Paget disease: scaly nipple, often associated DCIS/IDC underneath
— ER/PR positive: endocrine therapy (tamoxifen pre, AI post)
— HER2 positive: trastuzumab ± pertuzumab; cardiac monitoring (ejection fraction)
— Triple-negative: chemotherapy mainstay; consider pembrolizumab; BRCA testing for everyone diagnosed ≤60
— No routine CT/bone scan/PET in clinical stage I/II asymptomatic breast cancer
— No routine tumor markers (CA 15-3, CEA) in surveillance
— Mammography reduces breast cancer mortality ~20% relative; NNS ~1,000 over 10 years for women 50–74
— Sensitivity ~85%, specificity ~90%, PPV of abnormal screen ~5–10%
Key distinction: DCIS is stage 0 (treated and curable >95%); LCIS is a risk marker, not a cancer — managed with surveillance and chemoprevention, not surgery (except pleomorphic variant).
— 39-year-old average-risk asymptomatic woman asks when to begin screening
— Answer: biennial mammography at age 40 (USPSTF 2024)
— Distractor: "start at 50" (old 2016 USPSTF — wrong now)
— 76-year-old healthy, life expectancy 12 years, asks about continuing mammograms
— Answer: continue screening based on shared decision-making; USPSTF gives I, ACS/ACOG support continuing if life expectancy ≥10 yrs
— Distractor: "stop at 75" — too rigid
— Patient with mother breast cancer at 45 + maternal aunt ovarian cancer at 60
— Answer: refer for genetic counseling, then testing if appropriate; consider Tyrer-Cuzick for MRI eligibility
— Distractor: "order BRCA testing now" without counseling
— Patient's screening mammogram is BI-RADS 0
— Answer: diagnostic mammogram ± targeted ultrasound
— Distractors: repeat screening in 1 year, MRI, biopsy
— 32-year-old with new 2 cm firm mass
— Answer: ultrasound first (<30 yrs); add diagnostic mammogram if suspicious or ≥30
— Distractor: "reassure and follow in 3 months" — wrong for any persistent dominant mass
— Postmenopausal woman, Gail 5-yr risk 3%, ADH on biopsy
— Answer: offer aromatase inhibitor (or raloxifene)
— Distractor: tamoxifen first-line in postmenopausal (acceptable but not best given VTE/endometrial risk)
— 26-year-old BRCA2 positive
— Answer: annual breast MRI now; add mammography at 30
— Distractor: start both modalities at 25 (extra radiation)
— Non-lactating woman, failed two antibiotic courses
— Answer: biopsy (skin + breast core) for inflammatory breast cancer
— Distractor: another antibiotic, MRI
— Postmenopausal woman 3 yrs on tamoxifen with vaginal bleeding
— Answer: endometrial biopsy (not just TVUS)
— Patient asks about supplemental MRI for dense breasts alone
— Answer: discuss benefits/harms; USPSTF gives I statement; reasonable to offer but not mandated
CCS pearl: On CCS cases, the highest-yield orders for a routine screening visit are screening mammogram, family history update, risk assessment tool, and lifestyle counseling (alcohol, exercise, weight) — not a flurry of labs or imaging.
For average-risk women, biennial screening mammography from age 40 to 74 (USPSTF Grade B, 2024) is the cornerstone of breast cancer screening; high-risk women — defined by ≥20% lifetime risk, BRCA1/2 or other pathogenic variants, or prior chest radiation — additionally require annual breast MRI starting earlier, while shared decision-making, genetic counseling referral, and chemoprevention with tamoxifen, raloxifene, or aromatase inhibitors round out the comprehensive preventive plan.
— Start at 40, biennial, stop at 74 for average risk (USPSTF 2024). Continue past 75 only if life expectancy ≥10 yrs and patient prefers.
— BI-RADS 0 = need diagnostic imaging now; BI-RADS 3 = 6-month follow-up; BI-RADS 4/5 = core needle biopsy.
— High-risk pathway: lifetime risk ≥20% by Tyrer-Cuzick, BRCA1/2 or equivalent variant, or chest RT age 10–30 → annual MRI + mammography; BRCA carriers begin MRI at 25, mammography at 30.
— Chemoprevention (USPSTF Grade B): offer tamoxifen (any menopausal status), raloxifene or AI (postmenopausal) to women ≥35 with elevated Gail risk and low harm risk — counsel VTE, endometrial cancer (tamoxifen), bone loss (AI).
— Palpable mass, bloody unilateral discharge, persistent "mastitis," skin retraction = diagnostic pathway, not screening
— Genetic counseling before BRCA testing
— Document shared decision-making for ages 40–49 and ≥75
— Diagnostic mammography (not screening) and ultrasound first for any symptomatic patient or BI-RADS 0 recall
Board pearl: If a single Step 3 question on this topic distills to one decision, it is almost always: given this woman's age, risk profile, and current finding, what is the single next best step? — answer by anchoring on USPSTF 2024, then modifying for risk tier (average vs increased vs high), then pivoting to diagnostic workup if any symptom or BI-RADS 0/3/4/5 is present.